ROS1 positive

This real-world analysis provides contemporary insight into rebiopsy practices and longitudinal treatment patterns in oncogene-driven NSCLC. By mapping biopsy events to treatment trajectories, this study highlights evolving real-world practice, with rebiopsy rates at progression increasing over time across EGFR, ALK, and ROS1 cohorts.

Many repotrectinib AEs, including neurological AEs secondary to TRK inhibition, were mitigated with appropriate management, including dose modification and/or pharmacologic intervention.

When compared with the model group, TWL, MWT, the total distance traveled and the time spent in the center of open field test were elevated (P<0.01); the protein expression of TNF-α and IL-1β decreased (P<0.05), and that of IL-10 rose (P<0.05); the positive expression of Iba-1, and the co-expression of CD68 and Iba-1 were declined (P<0.01), and that of CD206 and Iba-1 increased in the EA group (P<0.01). EA at "Yanglingquan" (GB34) and "Dubi" (ST35) can attenuate pain and anxiety-like behaviors in the KOA rats with chronic pain and related negative emotions, and its underlying mechanism may be related to inhibiting microglia activity and promoting the polarization of activated microglia towards M2 phenotype in ACC.

Psychiatric manifestations were most pronounced: olfactory hallucinations (0.14%, ROR: 91.44, PRR: 91.31), auditory hallucinations (1.3%, ROR: 22.0, PRR: 21.7), and acute psychosis (0.2%, ROR: 22.12, PRR: 22.07).ConclusionsLorlatinib exhibits a multidimensional neuropsychiatric profile with rare but highly specific events. Proactive monitoring of cognitive, mood, speech, and psychotic domains is recommended in clinical practice.

P3, N=194, Recruiting, Nuvation Bio Inc. | N=138 --> 194

P2, N=27, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

P=N/A, N=97, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | Trial completion date: Mar 2027 --> Nov 2026 | Trial primary completion date: Mar 2027 --> Nov 2026

The patient received treatment with crizotinib and entrectinib successively. No new severe drug-related adverse events were observed. This case suggests that in patients with ROS1 fusion-positive nonsmall cell lung cancer who have experienced prior ROS1-tyrosine kinase inhibitor treatment failure and concomitant severe renal insufficiency, repotrectinib may represent a potential and tolerable treatment option when fully assessing clinical risks and ensuring close monitoring.

103 patients (95.4%) received ≥1 line of systemic anticancer therapy (SACT), of which 65 (63.1%) received first-line targeted therapy, mostly crizotinib monotherapy (n = 45) or crizotinib-based regimens (n = 10), with a median (95% CI) rwPFS and OS of 14.0 (8.3-19.8) and 47.9 (27.3-not estimable) months, respectively...Results from this study indicated a tendency for longer survival using currently available ROS1-targeted versus non-targeted therapy for patients with ROS1-positive advanced NSCLC. Nevertheless, survival outcomes were limited, highlighting the importance of more effective emerging treatments for ROS1-positive disease.

She was initiated on crizotinib, which led to a remarkable clinical response and tumor regression. Absolute diagnosis of pleural neoplasia can be daunting because of nonspecific imaging and cytology findings, more so if the pathology is in the fibrotic pleura. Pleural cryobiopsy, which employs a semirigid thoracoscope, makes room for larger and better-preserved tissue samples, enhancing the diagnostic yield in complicated scenarios like ours.

P3, N=71, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Sep 2033 --> Jun 2030 | Trial primary completion date: Aug 2032 --> Dec 2026